Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 805,900 shares, a growth of 8.7% from the February 13th total of 741,100 shares. Based on an average daily volume of 108,100 shares, the days-to-cover ratio is currently 7.5 days.
Alpine Immune Sciences Price Performance
Shares of ALPN stock opened at $8.04 on Thursday. Alpine Immune Sciences has a 12-month low of $4.82 and a 12-month high of $10.30. The firm has a market capitalization of $244.42 million, a price-to-earnings ratio of -4.49 and a beta of 1.29. The business has a 50 day simple moving average of $8.03 and a 200 day simple moving average of $7.20.
Hedge Funds Weigh In On Alpine Immune Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Decheng Capital Management III Cayman LLC boosted its stake in Alpine Immune Sciences by 42.5% during the 3rd quarter. Decheng Capital Management III Cayman LLC now owns 6,708,288 shares of the biotechnology company’s stock valued at $48,300,000 after purchasing an additional 2,000,000 shares in the last quarter. RA Capital Management L.P. boosted its stake in Alpine Immune Sciences by 0.9% during the 4th quarter. RA Capital Management L.P. now owns 4,397,368 shares of the biotechnology company’s stock valued at $32,321,000 after purchasing an additional 40,736 shares in the last quarter. Lynx1 Capital Management LP boosted its stake in Alpine Immune Sciences by 58.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 3,056,420 shares of the biotechnology company’s stock valued at $22,006,000 after purchasing an additional 1,129,551 shares in the last quarter. Commodore Capital LP bought a new position in Alpine Immune Sciences during the 3rd quarter valued at $9,540,000. Finally, Vanguard Group Inc. boosted its stake in Alpine Immune Sciences by 78.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,122,800 shares of the biotechnology company’s stock valued at $8,084,000 after purchasing an additional 493,027 shares in the last quarter.
Analysts Set New Price Targets
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.